Umbrella study
Showing 1 - 25 of 388
Data Related to Patients With Cancer
Not yet recruiting
- Cancer
- (no location specified)
Aug 28, 2023
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- A1:SG with SHR3680
- +7 more
- (no location specified)
Jun 23, 2023
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)
Not yet recruiting
- Breast Cancer
- +2 more
- Alpelisib
- +3 more
-
Stanford, CaliforniaStanford University
Nov 16, 2022
Breast Cancer, Metastatic Breast Cancer Trial (Elacestrant, Alpelisib, Everolimus)
Not yet recruiting
- Breast Cancer
- Metastatic Breast Cancer
- Elacestrant
- +4 more
- (no location specified)
Sep 28, 2022
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
Type 2 Diabetes Trial in United States (Produce Prescription)
Enrolling by invitation
- Type 2 Diabetes
- Produce Prescription
-
Chicago, Illinois
- +4 more
Oct 3, 2023
Hearing Loss Trial in Melbourne (Investigational Pre-Processing Algorithm, Cochlear Limited standard-of-care pre-processing
Not yet recruiting
- Hearing Loss
- Investigational Pre-Processing Algorithm
- Cochlear Limited standard-of-care pre-processing algorithms
-
Melbourne, Victoria, Australia
- +1 more
Oct 19, 2023
Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or
Recruiting
- Triple-negative Breast Cancer
- Pyrotinib with Capecitabine
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2022
Colorectal Cancer, Resectable Colorectal Carcinoma Trial in Milan (Trastuzumab deruxtecan, Durvalumab, Panitumumab)
Active, not recruiting
- Colorectal Cancer
- Resectable Colorectal Carcinoma
- Trastuzumab deruxtecan
- +4 more
-
Milan, Lombardia/MI, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Apr 26, 2023
Prostate Cancer Trial in Vancouver, Toronto (Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab)
Recruiting
- Prostate Cancer
- Apalutamide 60mg Tab
- +5 more
-
Vancouver, British Columbia, Canada
- +1 more
May 25, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Enfortumab vedotin)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Enfortumab vedotin
-
Salt Lake City, UtahHuntsman Cancer Institute
Jan 24, 2023
HNSCC, Head and Neck Tumors Trial in Seoul (BYL719, Poziotinib, Nintedanib)
Completed
- HNSCC
- Head and Neck Neoplasms
- BYL719
- +4 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 27, 2022
Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)
Not yet recruiting
- Advanced Breast Cancer
- Fulvestrant
- +4 more
-
Lebanon, New HampshireDartmouth Hitchcock Medical Center
Jun 28, 2023
Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)
Recruiting
- Breast Cancer
- Metastatic Cancer
- SHR7390
- +14 more
-
Shanghai, Shanghai, ChinaCancer Hospital Affiliated to Fudan University
Jul 22, 2022
Advanced Breast Cancer Trial in Seoul (Olaparib, Fulvestrant)
Not yet recruiting
- Advanced Breast Cancer
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 12, 2022
Hearing Loss Trial in Australia, Belgium (OPAL Sound Processing Strategy., OPAL-EM, SPACE)
Recruiting
- Hearing Loss
- OPAL Sound Processing Strategy.
- +6 more
-
Carlton, Victoria, Australia
- +4 more
Aug 10, 2022
Clinical Lactation Study on Exposure to Medicines Via Human Milk
Recruiting
- Breast Feeding
- Human Milk
- Human milk collection
- +2 more
-
Leuven, Vlaams-Brabant, BelgiumUniversitaire Ziekenhuizen KU Leuven
Sep 11, 2023
HER2-positive Gastric Cancer Trial in Seoul (Tislelizumab+Zanidatamab)
Not yet recruiting
- HER2-positive Gastric Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Feb 25, 2022
Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jan 30, 2023
Hearing Loss Trial in Lone Tree, Melbourne (the Mobile Research App, SOC/validated delivery of the speech perception test
Not yet recruiting
- Hearing Loss
- the Mobile Research App
- SOC/validated delivery of the speech perception test material
-
Lone Tree, Colorado
- +1 more
Oct 19, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (GP+DDP, Palbociclib, Intensity-modulated radiotherapy)
Not yet recruiting
- Nasopharyngeal Carcinoma
- GP+DDP
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 2, 2021
Bile Duct Cancer, Chemo Effect Trial in Seoul (AZD6738, Durvalumab, Olaparib)
Recruiting
- Bile Duct Cancer
- Chemotherapy Effect
- AZD6738
- +2 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 22, 2021
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023